Balanced news tone
News Sentiment
IMTX sentiment intelligence
Immatics NV news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
50
Balanced news tone
32 relevant articles
News tone and price action are not far from neutral.
79/100 classification confidence.
directly relevant articles
high-authority source matches
-2.7% over one week, +3.2% over four weeks, trend inactive, and near fair-value range.
Price to book forward of Immatics N.V. – NASDAQ:IMTX
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
79/100 classification
One-week reaction
-2.7%
Price reacting lower
Trend fit
Trend inactive
3.2% over four weeks
Fair value
4.5%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
3
Neutral
24
Negative
5
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
TradingView
Direct company coverage
Price to book forward of Immatics N.V. – NASDAQ:IMTX
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jun 2026 20:54
- Source
- TradingView
Stock Titan
Direct company coverage
Immatics (IMTX) director receives 48,000 stock options vesting in 2026
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 07:00
- Source
- Stock Titan
simplywall.st
Direct company coverage
Immatics (IMTX) Stock Looks Expensive After PRAME Platform Update And Cash Runway To 2028
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 18 Jun 2026 07:00
- Source
- simplywall.st
Stock Titan
Direct company coverage
Immatics (IMTX) director Adam Leo Stone receives 48,000 stock options award
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 07:00
- Source
- Stock Titan
Seeking Alpha
Direct company coverage
Immatics: PRAME Is Becoming More Than A Single-Asset Story (NASDAQ:IMTX)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jun 2026 07:00
- Source
- Seeking Alpha
GlobeNewswire
Direct company coverage
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jun 2026 12:00
- Source
- GlobeNewswire
GlobeNewswire
Direct company coverage
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 31 May 2026 13:00
- Source
- GlobeNewswire
Stock Titan
Direct company coverage
Immatics starts dual-target lung cancer trial designed to broaden patient reach
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 31 May 2026 07:00
- Source
- Stock Titan
Stock Traders Daily
Direct company coverage
Precision Trading with Immatics N.v. (IMTX) Risk Zones
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 31 May 2026 07:00
- Source
- Stock Traders Daily
GlobeNewswire
Direct company coverage
Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 May 2026 12:00
- Source
- GlobeNewswire
Simply Wall St.
Direct company coverage
Analysts Are Updating Their Immatics N.V. (NASDAQ:IMTX) Estimates After Its First-Quarter Results
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 15 May 2026 10:59
- Source
- Simply Wall St.
simplywall.st
Direct company coverage
Immatics N.V. (NASDAQ:IMTX) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
simplywall.st
Industry context
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
MT Newswires
Direct company coverage
Immatics Q1 Loss Widens, Revenue Falls
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 12 May 2026 11:40
- Source
- MT Newswires
Associated Press
Direct company coverage
Immatics: Q1 Earnings Snapshot
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 12 May 2026 11:17
- Source
- Associated Press
GlobeNewswire
Direct company coverage
Immatics Announces First Quarter 2026 Financial Results and Business Update
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 12 May 2026 07:00
- Source
- GlobeNewswire
Market source
Direct company coverage
Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 12 May 2026 07:00
- Source
- Market source
simplywall.st
Industry context
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Market source
Direct company coverage
All You Need to Know About Immatics (IMTX) Rating Upgrade to Buy
- Tone
- Positive 82/100
- Event
- Analyst action
- Published
- 06 May 2026 07:00
- Source
- Market source
Market source
Industry context
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Market source
Industry context
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
TradingView
Industry context
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Market source
Direct company coverage
Immatics N.V. (IMTX) Seeing Strong Enrollment in a Key Phase 3 Trial of Drug Candidate
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 13 Mar 2026 07:00
- Source
- Market source
Seeking Alpha
Direct company coverage
Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot (NASDAQ:IMTX)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Mar 2026 07:00
- Source
- Seeking Alpha
Seeking Alpha
Direct company coverage
Immatics: PRAME Leader's Transition To Commercial Reality
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Dec 2025 08:00
- Source
- Seeking Alpha
Quiver Quantitative
Direct company coverage
Immatics N.V. Announces Agreement to Sell 12.5 Million Ordinary Shares in Underwritten Offering
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 05 Dec 2025 08:00
- Source
- Quiver Quantitative
Stock Titan
Direct company coverage
Immatics N.V (IMTX) Stock Price, News & Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Apr 2025 01:22
- Source
- Stock Titan